PITTSBURGH– April 11, 2017 - Helomics® Corporation (Helomics), a privately-held, healthcare company providing personalized medicine solutions for clients in the pharmaceutical, diagnostic, and biotech industries, today announced the formation of an Advisory Board with over 100 years of combined experience in pharmaceutical, diagnostic, biotechnological, and clinical research industries. The first renowned professionals to accept seats on Helomics’ Advisory Board include Dr. Amelia Warner of Global Specimen Solutions and Dr. Paul Kornblith, Founder and former Chairman and CEO of Precision Therapeutics (later renamed Helomics) and the current Medical Advisor at Helomics.
Amelia Wall Warner, PharmD, RPh, is the Founder and CEO of Global Specimen Solutions, Inc. Dr. Warner served as CEO, President and Director of the Board for Gentris Corporation; Head of Clinical Pharmacogenomics and Clinical Specimen Management for Merck Research Laboratories (MRL); Chair of the Industry Pharmacogenomics Working Group (I-PWG); and as a PhRMA Representative to ICH E16- Genomic Biomarkers Related to Drug Response. Dr. Warner holds a B.S. degree in Biology from Wake Forest University and a PharmD degree from the University of North Carolina at Chapel Hill. Dr. Warner stated, “Helomics is a recognized leader in the development and commercialization of personalized medicine clinical lab tests in oncology. I am looking forward to assisting them in building their contract research services business in the bioscience industries.”
Paul Kornblith, M.D., currently serves as the Medical Advisor to Helomics, the Pittsburgh Life Sciences Greenhouse, and the Innovation Institute; as an Adjunct Professor in the School of Health and Rehabilitation at the University of Pittsburgh; and as the Western Pennsylvania Director for Life Sciences PA. A world-renown neurosurgeon, clinician, and clinical cancer researcher, Dr. Kornblith has authored over 150 peer-reviewed publications, 30 textbook chapters, and four textbooks. Dr. Kornblith also served as Vice Chairman of the Department of Neurosurgery at the University of Pittsburgh Medical School and the University of Pittsburgh Medical Center; Professor and Chairman of the Department of Neurosurgery at the Albert Einstein College of Medicine and Montefiore Hospital in New York; Chief of the Surgical Neurology Branch and Interim Clinical Director of the Neurological Institute at the National Institutes of Health in Bethesda, MD; Assistant Professor of Surgery and Director of the Cancer Program Project in the Department of Neurosurgery at Harvard University, and as an Attending Neurosurgeon at the Massachusetts General Hospital in Boston; and Editor-and-Chief of the Journal of Neuro-Oncology. Dr. Kornblith received his B.A. degree from Temple University and his M.D degree from Thomas Jefferson Medical School. Dr. Kornblith said, “I am very pleased to be working with Helomics, a leading clinical research laboratory that provides a well-characterized tissue culture-based system to determine the efficacy of the new and exciting modalities being developed for the personalized treatment of cancer.”
“We are fortunate to have two very talented and accomplished industry leaders as the initial appointees to our Advisory Board,” stated Gerald J. Vardzel Jr., President and CEO of Helomics. “Drs. Warner and Kornblith each bring a wealth of scientific, technical and business experience that will be invaluable to Helomics as we expand our contract research and clinical laboratory offerings. Over the next few weeks, we will be announcing the appointment of additional industry leaders to our Board of Advisors.”
About Helomics® Corporation
Helomics® is an integrated clinical contract research organization whose mission is to improve patient care by partnering with pharmaceutical, diagnostic, and academic organizations to bring innovative clinical products and technologies to the marketplace. Helomics offers advanced clinical laboratory diagnostic tests as well as scientific and non-scientific product enhancement services to provide a customized solution to our client’s specific product development needs.
Helomics® is headquartered in Pittsburgh, Pennsylvania where the company maintains state-of-the-art, CLIA-certified, clinical and research laboratories. For more information please visit: www.helomics.com.
Safe Harbor Statement
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release may contain forward-looking information within the meaning of Section 27A Of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words “believes”, “expects”, “anticipates” or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from those expressed or implied by such forward-looking statements.
For more information regarding Helomics Corporation, please contact:
Michelle Murgia, Marketing Communications and Design
Sources: Helomics® Corporation